Copyright
©The Author(s) 2019.
World J Gastroenterol. May 14, 2019; 25(18): 2229-2239
Published online May 14, 2019. doi: 10.3748/wjg.v25.i18.2229
Published online May 14, 2019. doi: 10.3748/wjg.v25.i18.2229
Table 2 Adverse events reported during the HEARTLAND study
| Most common adverse events | Patients reporting AE (n = 100) |
| Fatigue | 12 (12%) |
| Headache | 10 (10%) |
| Insomnia | 9 (9%) |
| Diarrhea | 8 (8%) |
| Anemia | 6 (6%) |
| Nausea | 6 (6%) |
| Pruritus | 5 (5%) |
| Rash | 4 (4%) |
| Upper respiratory infection | 3 (3%) |
| Urinary tract infection | 3 (3%) |
- Citation: Loo N, Lawitz E, Alkhouri N, Wells J, Landaverde C, Coste A, Salcido R, Scott M, Poordad F. Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients. World J Gastroenterol 2019; 25(18): 2229-2239
- URL: https://www.wjgnet.com/1007-9327/full/v25/i18/2229.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i18.2229